Research Radartracking 1,316 published studies · 343 human · 8 safety signals · 43 clinical trials · 44 cancer pages · updated Aug 2026Open the Research Map →

Liposomal Doxorubicin

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceInsufficient evidenceInconclusive
1 published studies tagged to this agent0 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?

Insufficient evidence — No primary experimental studies yet.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Auto-discovered · not yet curatedliposomal doxorubicin
Educational only, not medical advice. OncoForge makes no claim that Liposomal Doxorubicin treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Auto-discovered from 1 recent study; not yet curated.

Research

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CancerHuman evidenceMechanismSafetyTrial
Advanced Or Metastatic High Grade Epithelial Ovarian Cancer—1—1
High Grade Epithelial Ovarian Cancer—1—1
Ovarian Epithelial Carcinoma—1—1

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
0
Observational
0
Case report
0
Review
1
Preclinical
0
Other
0
1 studies1 review/other

Tracking 1 published study of Liposomal Doxorubicin: 1 reviews/other.

Reported direction across studies: 1 inconclusive.

No human studies yet — these are preclinical (lab/animal) findings that may not translate to people.

These counts summarize what the studies reported; they are not a measure of whether Liposomal Doxorubicin works.

Cancers named in these studies

advanced or metastatic high-grade epithelial ovarian cancer (1)high-grade epithelial ovarian cancer (1)ovarian epithelial carcinoma (1)

All studies

ReviewTrialInconclusiveLimited evidenceTier 4 · clinicaln = 11

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer

Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review

BevacizumabAnastrozoleCisplatinGemcitabineTopotecanOlaparibNiraparibCarboplatinLiposomal-doxorubicinPaclitaxelTamoxifenRucaparibadvanced or metastatic high-grade epithelial ovarian cancerhigh-grade epithelial ovarian cancerovarian epithelial carcinoma

This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.

Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.

Key findings
  • The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
  • Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
  • Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
  • PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
  • For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..

Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

What changed recently

The latest additions to Liposomal Doxorubicin's evidence base, and anything that's been retracted.

Recently added

Evidence at a glance: Liposomal Doxorubicin by cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Advanced or metastatic high-grade epithelial ovarian cancerInsufficient evidenceInconclusive

No primary experimental studies yet.

Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer

No human studies yet · No numeric effect sizes reported · Based on a single study.
High-grade epithelial ovarian cancerInsufficient evidenceInconclusive

No primary experimental studies yet.

Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer

No human studies yet · No numeric effect sizes reported · Based on a single study.
Ovarian epithelial carcinomaInsufficient evidenceInconclusive

No primary experimental studies yet.

Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer

No human studies yet · No numeric effect sizes reported · Based on a single study.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Liposomal Doxorubicin depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies

Clinical trials studying Liposomal Doxorubicin

1 ongoing · 2 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
2 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar